Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (215)

11

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

12

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma : importance of immunoglobulin supplementation

enthalten in: Blood advances | 2024

von Frerichs, K. | Verkleij, C. | Mateos, M. | +21

13

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

14

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA

enthalten in: Current opinion in oncology | 2023

von van de Donk, N. | O'Neill, C. | de Ruijter, M. | +2

15

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129) : final analysis of a non-randomised, multicentre, phase 2 study

enthalten in: The Lancet. Oncology | 2023

von van de Donk, N. | Minnema, M. | van der Holt, B. | +25

16

Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von van der Schans, J. | Wang, Z. | van Arkel, J. | +11

17

Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

enthalten in: Future oncology (London, England) | 2023

von Chari, A. | Askari, E. | Caers, J. | +9

18

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice : A Modified Delphi Study

enthalten in: HemaSphere | 2023

von Ramasamy, K. | Avet-Loiseau, H. | Hveding Blimark, C. | +8

ErratumIn: Hemasphere. 2023 Nov 02;7(11):e986. - PMID 37928623

19

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients : Long-term Results of HOVON-126/NMSG 21.13

enthalten in: HemaSphere | 2023

von Groen, K. | Schjesvold, F. | van der Holt, B. | +22

20

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma : an open-label phase 2 trial

enthalten in: EClinicalMedicine | 2023

von Groen, K. | Stege, C. | Nasserinejad, K. | +26